Rani Therapeutics Holdings Inc [NASDAQ: RANI] surged by $0.11 during the normal trading session on Tuesday and reaching a high of $2.05 during the day while it closed the day at $1.89.
Rani Therapeutics Holdings Inc stock has also loss -33.68% of its value over the past 7 days. However, RANI stock has inclined by 245.46% in the 3 months of the year. Over the past six months meanwhile, it has gained 70.27% and lost -20.92% year-on date.
The market cap for RANI stock reached $135.83 million, with 47.90 million shares outstanding and 40.07 million shares in the current float. Compared to the average trading volume of 14.28M shares, RANI reached a trading volume of 12423981 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Rani Therapeutics Holdings Inc [RANI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RANI shares is $9.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RANI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Rani Therapeutics Holdings Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 02, 2024. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on June 14, 2024, representing the official price target for Rani Therapeutics Holdings Inc stock. Previously, the target price had yet another raise to $10, while Rodman & Renshaw analysts kept a Buy rating on RANI stock.
RANI stock trade performance evaluation
Rani Therapeutics Holdings Inc [RANI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -33.68. With this latest performance, RANI shares gained by 285.71% in over the last four-week period, additionally plugging by 70.27% over the last 6 months – not to mention a rise of 37.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RANI stock in for the last two-week period is set at 64.53, with the RSI for the last a single of trading hit 0.5045, and the three-weeks RSI is set at 0.3190 for Rani Therapeutics Holdings Inc [RANI]. The present Moving Average for the last 50 days of trading for this stock 0.7586, while it was recorded at 1.9990 for the last single week of trading, and 0.9339 for the last 200 days.
Rani Therapeutics Holdings Inc [RANI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Rani Therapeutics Holdings Inc [RANI] shares currently have an operating margin of -3796.75% and a Gross Margin at 15.33%. Rani Therapeutics Holdings Inc’s Net Margin is presently recorded at -2473.83%.
Rani Therapeutics Holdings Inc (RANI) Capital Structure & Debt Analysis
Rani Therapeutics Holdings Inc (RANI) Efficiency & Liquidity Metrics
Rani Therapeutics Holdings Inc (RANI) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Rani Therapeutics Holdings Inc. (RANI) effectively leverages its workforce, generating an average of -$282761.9 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.54% and a Quick Ratio of 0.54%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Rani Therapeutics Holdings Inc [RANI] stock
With the latest financial reports released by the company, Rani Therapeutics Holdings Inc posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.29/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RANI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rani Therapeutics Holdings Inc go to 39.02%.
Rani Therapeutics Holdings Inc [RANI]: Institutional Ownership
There are presently around $20.83%, or 22.57%% of RANI stock, in the hands of institutional investors. The top three institutional holders of RANI stocks are: VANGUARD GROUP INC with ownership of 0.71 million shares, which is approximately 2.7265%. NAN FUNG GROUP HOLDINGS LTD, holding 0.49 million shares of the stock with an approximate value of $$1.88 million in RANI stocks shares; and NAN FUNG GROUP HOLDINGS LTD, currently with $$1.7 million in RANI stock with ownership which is approximately 1.7227%.
